### Ocular Therapeutix™ Launches Bold New Corporate Branding
**BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE)** — In an exciting move, **Ocular Therapeutix, Inc.** (NASDAQ: OCUL) has unveiled its vibrant new corporate branding and website. This launch signals the next phase of the company’s commitment to transforming the **retina experience** for patients.
*Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular “O” represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the “X” symbolizes the intersection of the company’s journey.*
### A Vision for Change
**“Retinal disease**, particularly **wet age-related macular degeneration (AMD)**, remains a leading cause of blindness due to the high burden of existing treatments,” emphasized **Pravin U. Dugel, MD**, Executive Chairman, President, and CEO of Ocular Therapeutix. “At Ocular, we aim to redefine the retina experience, alleviating that burden to help preserve vision over the long term. Our new branding reflects our significant progress and the momentum from our SOL trials, highlighting our unwavering commitment to patients.”
#### The Power of New Branding
The new identity is not just aesthetic; it embodies Ocular Therapeutix’s mission to disrupt the status quo in retinal disease treatment. With **wet AMD** affecting **1.8 million** people in the U.S. alone, the burdensome current treatment options often require up to **12 injections** a year, leading to treatment discontinuation and poor long-term outcomes.
**One in four patients** may develop fibrosis within two years, and many experience atrophy within just **five years** of treatment. Ocular’s investigational therapy, **AXPAXLI™** (also known as **OTX-TKI**), seeks to revolutionize this approach with a more durable and effective solution via intravitreal injection.
### A New Era at Ocular Therapeutix
Ocular’s rebranding has launched across its website and social media platforms and will make its grand debut at the **American Society of Retina Specialists (ASRS)** conference.
**Explore the new corporate branding on our** [website](https://www.globenewire.com/Tracker?data=4luokMmc3zWpL68sYbFGkJiV69g3U8sc5I-xuqHwCVrlCxov_tdNNhGOsmyHk7kEw-bfSbokWUKVC95nAh_0gQ==).
### About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully integrated biopharmaceutical company focused on redefining the retina experience. **AXPAXLI™**, their investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on their proprietary **ELUTYX™** technology. Currently, AXPAXLI is in **Phase 3 clinical trials** for wet AMD.
In addition to AXPAXLI, Ocular’s pipeline also features **DEXTENZA®**, an FDA-approved corticosteroid designed to treat ocular inflammation and pain, along with **OTX-TIC**, a travoprost intracameral hydrogel in Phase 2 trials targeting open-angle glaucoma.
### Stay Connected
Follow Ocular Therapeutix on their [website](https://www.ocutx.com), [LinkedIn](https://www.linkedin.com/company/oculartherapeutix), and [X](https://twitter.com/OcularTherapeutix) for the latest updates in retinal care.
**Investors & Media Contact:**
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
—
Ocular Therapeutix is paving the way for revolutionary changes in retinal disease management, demonstrating that effective branding can significantly enhance a company’s identity and mission in the biopharmaceutical landscape.
